Unveiling New Insights and Treatment Options for Ocular Surface Diseases

Dear Colleagues,

Ocular surface diseases comprise a spectrum of disorders that affect the surface of the eyes, including dry eye disease (DED), neurotrophic keratitis (NK), and neuropathic corneal pain (NCP). These diseases can have significant impacts on visual acuity, comfort, and quality of life for affected individuals. Ocular surface diseases share a common feature of inflammation and immune responses driving their pathogenesis and progression. Inflammatory processes lead to the release of neuromediators and growth factors, contributing to the development and symptoms of ocular surface diseases. Insights into the underlying mechanisms of ocular surface diseases hold great promise for the identification of novel biomarkers and the development of targeted treatments that specifically address the molecular pathways involved in these diseases. This personalized approach is expected to enhance treatment efficacy and improve patient outcomes.

We are pleased to invite colleagues working in any field related to ocular surface diseases, from drug design and formulation to drug delivery and treatment, to submit their work for publication in this Special Issue. We are confident that, through the publication of innovative research, insightful reviews, and cutting-edge studies, this Special Issue in Pharmaceutics will help foster interdisciplinary collaboration and stimulate the further exploration of novel approaches and therapeutic strategies for ocular surface diseases. We encourage researchers and experts to contribute their valuable work to this issue, as together, we can advance our understanding and improve the management of these challenging conditions.

This Special Issue aims to provide a platform for scientists to publish their experimental results, novel findings, innovative methodologies, and theoretical assumptions in the field of ocular surface diseases. By providing an avenue for researchers to share their findings and insights, we aim to promote further exploration and advancements in this area of research. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: pharmaceutical sciences, ophthalmology, immunology, and bioengineering.

We look forward to receiving your contributions.

You may choose our Joint Special Issue in Pharmaceutics.

Dr. Paola Tirassa
Dr. Pamela Rosso
Dr. Fabiana Mallone
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Future Pharmacology is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.